Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

NCT06510283 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Interventions

DRUG: Taitacept

Sponsor

Beijing Tongren Hospital